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no association of complement 
mannose-binding lectin deficiency 
with cardiovascular disease in 
patients with Systemic Lupus 
Erythematosus
A. Kieninger-Gräfitsch  1*, S. Vogt1, c. Ribi2, D. Dubler1, c. chizzolini3, U. Huynh-Do4, 
M. osthoff1,5 & M. trendelenburg1,5
Cardiovascular (CV) morbidity is the major cause of death in patients with Systemic Lupus 
Erythematosus (SLE). Previous studies on mannose-binding lectin (MBL) gene polymorphisms in 
SLE patients suggest that low levels of complement MBL are associated with cardiovascular disease 
(CVD). However, as large studies on MBL deficiency based on resulting MBL plasma concentrations 
are lacking, the aim of our study was to analyze the association of MBL concentrations with CVD in 
SLE patients. Plasma MBL levels SLE patients included in the Swiss SLE Cohort Study were quantified 
by ELISA. Five different CV organ manifestations were documented. Of 373 included patients (85.5% 
female) 62 patients had at least one CV manifestation. Patients with MBL deficiency (levels below 
500 ng/ml or 1000 ng/ml) had no significantly increased frequency of CVD (19.4% vs. 15.2%, P = 0.3 
or 17.7% vs. 15.7%, P = 0.7). After adjustment for traditional CV risk factors, MBL levels and positive 
antiphospholipid serology (APL+) a significant association of CVD with age, hypertension, disease 
duration and APL+ was demonstrated. In our study of a large cohort of patients with SLE, we could not 
confirm previous studies suggesting MBL deficiency to be associated with an increased risk for CVD.
Systemic lupus erythematosus (SLE) is an idiopathic, chronic and highly heterogeneous inflammatory disorder, 
driven by an immune response against self-antigens. The prevalence generally ranges from 20 to 70 per 100.0001 
and affects both sexes of any age but predominates in women of childbearing age2 with a male-to-female ratio of 
about 9:13.
The etiology of SLE is multifactorial and the complexity of different factors (genetic, hormonal, immunolog-
ical and environmental) matches the diversity of clinical manifestations in SLE patients4. Associated with the 
presence of immune complexes, ongoing complement system activation leads to inflammation and consumption 
of complement proteins5. This chronic inflammatory state predisposes SLE patients to premature cardiovascular 
disease (CVD) and infections.
Premature CVD, mostly related to accelerated atherosclerosis6, is acknowledged as the major cause of death 
in SLE patients, regardless of the time after diagnosis7,8, resulting in a bimodal mortality curve, first described by 
Urowitz et al. in the 1970s9. The 5-year survival after diagnosis nowadays exceeds 90%10–12, but this survival rate 
has not improved since the 1980s.
The prevalence of ischemic heart disease in SLE patients is estimated to be between 3.8 and 16%13–18, a 10-fold 
higher prevalence compared to the general population19. Moreover, the risk of myocardial infarction in young 
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women with SLE has been found to be 50 times higher compared to women of similar age20 and the risk of stroke 
was found to be increased by 2–8 fold19,21,22.
As traditional Framingham risk factors (smoking, dyslipidemia, diabetes mellitus (DM), hypertension and 
overweight) cannot fully explain the high rates of ischemic events, SLE is nowadays considered an independent 
risk factor for CVD23.
Several studies suggest that components of the innate immune system, which includes pattern-recognition 
molecules of the complement system such as mannose-binding lectin (MBL), may play an additional role in 
the pathogenesis of atherosclerosis and CVD24–26. Among those, MBL is a liver-derived serum protein that 
binds certain sugars on the surface of pathogenic micro-organisms and cellular debris and, as it cannot directly 
opsonize pathogens, triggers complement activation via the lectin pathway27. MBL deficiency (<1000 ng/ml) 
is mostly caused by a three-point mutation (O alleles) in exon 1 of the MBL gene (in codon 52, 54, 57) that 
disrupts the assembly of the oligomers and also by a promotor polymorphism (LX) that is associated with low 
MBL production. However, despite carrying the same genotype, actual MBL levels can vary significantly between 
individuals27–29.
Previous studies indicate that genetic variability in MBL may be involved in the pathogenesis of SLE30, more 
precisely that functional MBL deficiency is associated with an increased susceptibility to SLE31. Furthermore, 
Panda et al. described that patients with low MBL-producing genotype have a predisposition to develop SLE32. 
However, data remains controversial as indicated by Losada Lopez et al. who only described a tendency to a 
higher allele B incidence in SLE patients33.
Independent of its association with SLE, MBL deficiency has been reported to be associated with an increased 
risk of atherosclerosis26 and coronary artery disease24 in the general population, and therefore, to be mostly disad-
vantageous in this regard24–26,34. Of note, Limnell et al. even described that MBL deficiency might lead to venous 
bypass graft occlusion in patients with coronary heart disease35. This observation is supported by another report 
on high MBL levels having a cardioprotective effect, i.e. being associated with a decreased risk for myocardial 
infarction (MCI) among patients with diabetes36. However, data are controversial as some studies show an associ-
ation of cardiovascular (CV) manifestations with MBL deficiency in the general population but others found no 
such link37–39. This controversy has also recently been summarized by Larsen et al.40. In addition, an association of 
deficiency of complement MBL with reduced mortality in patients with MCI undergoing percutaneous coronary 
intervention41 as well as with smaller cerebral infarcts and a favorable outcome42 has been described previously. 
These studies suggest that MBL deficiency – being rather disadvantageous with regard to atherosclerosis and the 
occurrence of CVD - has an advantageous effect on the outcome after CV events.
Inconsistencies among study results might in part be due to the retrospective character, the relatively small 
study populations or the focus on MBL2 gene polymorphisms but not on actual MBL plasma levels, which would 
implicate the MBL deficiency and which are also influenced by non-genetic factors such as inflammation43 and 
thyroid function44. Thus, as studies on MBL deficiency based on resulting MBL plasma concentrations were lack-
ing, this study was undertaken to determine the potential association between low MBL levels and the risk for 
CV events in SLE.
Methods
patients. 373 SLE patients included in the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS)45 were 
included in this study. SSCS is a nationwide, multicenter and ethics committee-approved longitudinal study of 
SLE patients living in Switzerland, conducted in 11 different institutions in 9 Swiss cities. All participants had to 
fulfill at least 3 out of 11 American College of Rheumatology (ACR) criteria for the classification as SLE at the 
time of inclusion and had to give written informed consent. In SSCS, the Systemic Lupus Erythematosus Disease 
Activity (SLEDAI) score with the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) 
modification and Physician’s Global Assessment (PGA) keeps record of the disease activity, while the Systemic 
Lupus International Collaborating Clinics (SLICC) damage index is used to document chronic organic damage 
that occurred after diagnosis.
For the analysis of potential confounders, we included common disease activity scores (SELENA-SLEDAI and 
PGA) and CV risk factors (smoking status, diabetes mellitus (DM), hypercholesterolemia, arterial hypertension, 
overweight, and positive antiphospholipid serology (APL+)). Since data on packyears (PY) in some cases were 
missing we additionally compared ever-smokers with non-smokers. We assumed hypercholesterolemia if patients 
had any form of treated hyperlipidemia, either familial or acquired, and/or met the common laboratory analytic 
criteria (cholesterol > 5.2 mmol/l and/or low-density lipoprotein (LDL) > 3.4 mmol/l). Similarly, patients were 
classified as being hypertensive if any treatment with antihypertensive medication was documented. Overweight 
was classified using the body-mass-index (BMI) that was calculated using the information that was available at 
study visits but did not take weight changes over time into account. APL+ was defined based on the specification 
of the SSCS45, more specifically as positive finding of antiphospholipid antibody based on an abnormal serum 
level of IgG or IgM anticardiolipin antibodies or IgG or IgM beta 2-glycoprotein antibodies or a positive test result 
for lupus anticoagulant using a standard method.
This study was approved by the Ethical Committee of the Canton Basel, Switzerland (Ref. No. EK 262/06), all 
further involved ethical committees and Swissethics (Ethical Committee of the Canton Vaud, Switzerland Ref No 
2017-01434). All subjects gave written informed consent in accordance with the Declaration of Helsinki.
evaluation and ascertainment of inclusion criteria and endpoint. Patients solely were selected 
based on the availability of complete disease activity score (SELENA-SLEDAI, PGA), SLICC damage index, 
and available plasma sample at the time of study visit. Demographic (e.g. age, ethnic background, disease, and 
follow-up duration), clinical, laboratory and treatment information were extracted from the cohort database.
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Patients were defined as having CVD if at least one CVD of the SLICC index was present. The following arte-
rial thrombotic events were included: (a.) cerebrovascular ischemia (CVI), (b.) coronary heart disease (CHD), (c.) 
myocardial infarction (MCI), (d.) peripheral artery disease (PAD) and (e.) mesenteric insufficiency.
Determination of MBL levels and definition of cut-offs. Plasma samples from the 373 SLE patients 
were collected between 2008 and 2018, which had been exclusively stored at −70 °C and had never been thawed 
before use. MBL levels were quantified using a mannan-binding enzyme-linked immunosorbent assay (ELISA), 
as described previously46. This assay measures the ability of MBL to bind to a mannan-coated surface. Microtitre 
plates (Maxi sorp, Thermo Denmark) were coated with 10 µg/ml of mannan (M7504, Sigma-Aldrich USA) in 
fresh carbonate–bicarbonate buffer (C3041, Sigma-Aldrich USA), pH 9.6, and incubated overnight at 4 °C. 
Plasma samples were tested as in a sandwich ELISA but with Tris-buffered saline with 0.05% Tween-20 (TBST) 
(P5927, Sigma-Aldrich USA) and Calciumchlorid-dihydrate (CaCl2) (21101, Sigma-Aldrich USA), pH 7.5, as 
both the diluent and wash buffer. All incubations were carried out at 22 °C. First, the microtitre plates were incu-
bated with samples at a 1:100 dilution for 90 minutes, followed by a biotinylated monoclonal anti-MBL anti-
body (HYB 131-01B, BioPorto Diagnostics, Denmark) for again 90 minutes to detect the bound MBL. After 
incubation with ExtrAvidin peroxidase conjugate (E2886, Sigma-Aldrich USA) for 40 minutes the plates were 
developed with BD TMB substrate solutions (555214, BD USA), stopped after 10 minutes with 0.5 M sulfuric acid 
(H2SO4) (1.00731, Merck Germany) and read immediately at 450 nm on a microplate biokinetics reader (BioTEK, 
Instruments, USA). MBL levels were calculated against a standard serum pool (ser101, BioPorto Diagnostics 
Denmark).
Taking the total number of CV events into account, we predefined two different cut-off levels for MBL defi-
ciency, at 500 ng/ml47 and 1000 ng/ml48, respectively, as described previously.
As a control, measurement of MBL level was repeated in 120 of our 373 included patients using samples from 
different study visits and serum samples instead of plasma samples to investigate the long-term stability and 
intra-individual variability of MBL levels in our patients and the potential influence of biosampling on our study 
results.
Statistical analysis. First, we examined the baseline characteristics of patients that developed or did not 
develop CVD using standard descriptive statistical tests. Data are presented as medians (interquartile range 
(IQR)) or frequencies with percentages when suitable. Beyond the use of predefined cut-offs for the definition of 
MBL deficiency, a ROC curve was established to explore the data for a potential cutoff level.
Analyzing the long-term stability and intra-individual variability of MBL levels we used Wilcoxon 
Signed-Ranks Test and Spearman rank correlation for the comparison of the two MBL concentrations that were 
measured in the same patients at two time points.
Pearson’s qui2  test and Fisher’s exact test, respectively, dependent on the group size, were used when compar-
ing the occurrence of CVD and categorical variables. We used the Mann-Whitney U Test and Kruskal-Wallis Test, 
respectively, when comparing continuous with categorical variables as well as linear regression when comparing 
two continuous variables. The frequencies of CVD dependent on MBL cut-off levels and MBL levels itself were 
compared for disease activity index and common CV risk factors as well as APL+. Subsequently, we repeated the 
analysis for all CVD subcategory.
Last, we analyzed the association of possible risk factors with the presence of CVD using logistic regression 
models. A multiple logistic regression analysis was performed, taking the dichotomized (yes/no) CVD in total as 
the dependent variable and those as independent variables that reached statistical significance in the univariate 
analysis and all variables, corresponding to traditional CV risk factors.
Two-tailed tests and a 5% significance level were used in all analyses. All reported P values of less than 0.05 
were considered to indicate statistical significance. The analysis was performed with the statistical package IBM 
SPSS Statistics 25 for MAC OS X, graphs were performed using the publicly available statistical program R.
In a first exploratory analysis of 177 SLE patients, a strong trend towards a significant difference in plasma 
MBL concentrations between patients with and without CVD was observed. We calculated an adequately pow-
ered study (80%) to require at least 362 SLE patients (alpha = 0.05 incidence of CVD 15% standard deviations as 
observed in the first 177 patients) in order to be able to detect a difference in MBL plasma levels of at least 450 ng/
ml in patients with versus without CVD. Based on this calculation, we selected a SLE patient population of 373 
patients to account for potentially missing data.
Statement. The abstract of this article is present on a university repository website and can be accessed 
on https://www.sgaim.ch/fileadmin/user_upload/Adaptionen/Congress/BilderHighres/Bilder_FK_2019/
Abstracts_2019.pdf. This article is not published nor is under publication elsewhere.
compliance with ethical standards. This study was approved by the Ethical Committee of the Canton 
Basel, Switzerland (Ref No EK 262/06), all further involved ethical committees and Swissethics (Ethical 
Committee of the Canton Vaud, Switzerland Ref. No. 2017-01434). All procedures performed in this study 
involving human participants were in accordance with the ethical standards of the research committee and with 
the 1964 Helsiniki declaration and its later amendments or comparable ethical standards. Informed consent was 
obtained from all individual participants included in the study.
Results
patients characteristics. The study population comprised 373 patients of whom 319 (85.5%) were female 
and 54 (14.5%) male. The median (Interquartile Range (IQR)) age at time of first clinical manifestation of SLE 
was 31.0 (21.6–43.9) years, the median age at the time of blood sampling 43.1 (32.2–54.3) years, the median age at 
SLICC index assessment 44.8 (34.6–57.5) years, and the median SLE duration at the time of damage assessment 
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since first clinical manifestation was 9.5 (5.2–18.1) years. Of all patients 74.5% were Caucasian, 10% African, 9.7% 
Asian, 5.1% Native Americans and 0,3% Pacific Islanders. At the time of the study visit 44.2% had a SLEDAI score 
of 6 or more (median (IQR) SLEDAI score 4 (2–9)) and 53.4% had a PGA equal to 1 or higher.
The basic demographic and clinical characteristics of all patients are summarized in Table 1.
MBL - Baseline associations and long-term stability. The median (IQR) MBL level was 1131 (335–
2344) ng/ml. 129 patients (34.6%) showed levels below 500 ng/ml and 175 patients (46.9%) below 1000 ng/ml 
(Table 1). MBL levels had no association with active disease (i.e. SLEDAI ≥ 6 or PGA ≥ 1) at the time of the study 
visit (p = 0.5 and p = 0.2, respectively). In addition, long-term stability and lack of significant intra-individual 
variability of MBL levels could be shown in 120 patients (32.2%) whose samples from different study visits were 
measured twice in different specimens (serum and plasma), at different time points (2014 and 2018) and by two 
different investigators.
MBL levels at the two different time points correlated significantly (Spearman’s rho Correlation Coefficient 
0.946, p < 0.001, Fig. 1) and did not change over time (median (IQR) levels (1222 (372–2035) ng/ml vs. 1131 
(336–2344) ng/ml) as determined by the Wilcoxon Signed Rank Test (Z = −1.717, p = 0.086).
Distribution data of MBL deficiency from healthy Swiss controls were not available. However, likewise to our 
study population, the frequency of MBL deficiency below 500 ng/ml in SLE patients of our study cohort (median 
(IQR) 1130 (340–2340) ng/ml, 34.6%) was similar (p = 0.22) to the frequency observed in Swiss scleroderma 
patients (median (IQR) 1290 (330–2300) ng/ml, 30.3%) as described previously49. This study showed a good 
sample size (=195) and is, therefore, comparable considering the close relationship between systemic sclerosis 
and SLE.
Furthermore, we investigated the potential association of erythrocyte sedimentation rate (ESR) as marker of 
inflammation with MBL levels. We observed a very weak correlation between MBL plasma concentration and 
the corresponding ESR (r = 0.12, p = 0.03) as well as the daily prednisolone (PDN) dose (r = 0.14, 0 = 0.04), 
respectively.
Study Population
Female, n (%) 319/373 (85.5)
Disease Classification at time of inclusion
American College of Rheumatology criteria, median (IQR) 5 (4–6)
Ethnicity
Caucasian, n (%) 278/371 (74.5)
African, n (%) 37/371 (10)
Asian, n (%) 36/371 (9.7)
Pacific Islander, n (%) 1/371 (0.3)
Native American, n (%) 19/371 (5.1)
Age
at first manifestation of SLE, median (IQR), n = 333/373 (89.3%) 31.0 (21.6–43.9)
at blood sampling, median (IQR) 43.1 (32.2–54.3)
at damage assessment, median (IQR) 44.8 (34.6–57.5)
Disease duration since first manifestation of SLE
at blood sampling, median (IQR), n = 333/373 (89.3%) 6.6 (2.3–16.2)
at damage assessment, median (IQR), n = 333/373 (89.3%) 9.5 (5.2–18.1)
Disease Activity at blood sampling
Systemic Lupus Erythematosus Disease Activity Index, ≥6, n (%) 165/373 (44.2)
Physician’s Global Assessment, ≥1, n (%) 199/373 (53.4)
SLICC Index at damage assessment, median (IQR), n = 364/373 (97.6%) 2.25 (0–5.7)
MBL Level (ng/ml), median (IQR) 1131 (336–2344)
<500 ng/ml, n (%) 129/373 (34.6)
<1000 ng/ml, n (%) 175/373 (46.9)
Potential confounders
Diabetes mellitus, n (%) 25/373 (6.7)
Hypertension, n (%) 127/306 (41.5)
Hypercholesterolemia, n (%) 67/128 (52.3)
Nicotine: Ever-smoker, n (%) 145/342 (42.4)
Body-mass index (kg/m2), median (IQR), n = 318/373 (85.3%) 23.4 (20.7–26.6)
            Overweight (BMI > 25 kg/m2), n (%) 112/318 (35.2)
Positive Antiphospholipid Serology, n (%) 162/371 (43.7)
Table 1. Demographic characteristics of 373 patients with systemic lupus erythematosus. n = 373, unless 
otherwise stated, IQR = interquartile range, % = percentage, SLICC = Systemic Lupus International 
Collaborating Clinics damage assessment.
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In addition, using a commonly used pathologic ESR cut-off level of 28 mm/h50, we saw a weak association 
between patients with an elevated ESR and a MBL deficiency below 1000 ng/ml (p = 0.047). However, this asso-
ciation was not found (p = 0.084) when using a 500 ng/ml cut-off. Further, we saw no such association between 
MBL deficiency and steroid intake, but as expected patients with a higher ESR were more likely to receive higher 
doses of PDN as part of the treatment (r = 0.3, p < 0.0001).
cVD. In total, 62 patients (16.6%) had at least one CV manifestation, of these patients 77.4% were Caucasians, 
11.3% African, 6.5% Asians and 4.8% Native Americans. 20 patients (5.3%) had more than one CVD manifes-
tation, leading to a total of 93 distinctive CVDs that were documented in the study population. Separated into 
subcategories, 10.2% of the patients had a CVI (38/373), 7.8% a CHD (20/373), 4.3% a MCI (16/373), 2.4% a PAD 
(9/373) and 1% (1/373) a documented mesenteric insufficiency. (supplemental Table 1)
Distribution of CVD risk factors in the study population and distribution of CVD according to age, disease 
duration, ethnicity, CV risk factors, and other confounders are shown in Tables 1 and 2, respectively.
Association of MBL deficiency cut-off levels and continuous MBL levels with CVD and confounders. Patients with 
MBL deficiency being defined as plasma concentrations below 500 ng/ml had no significantly increased, nor 
decreased, frequency of CVD (19.4% vs. 15.2%, P = 0.3). Similarly, MBL levels below 1000 ng/ml were not asso-
ciated with an increased rate of CVD (17.7% vs. 15.7%, P = 0.6). In addition, MBL deficiency was not associated 
with the occurrence of any subcategory of CVD.
Furthermore, MBL levels were similarly distributed in CVD versus no-CVD patients (median (IQR) 1180 
(339–2344) ng/ml vs. 955 (306–2389) ng/ml, p = 0.5, Fig. 2a). Last, an explorative receiver operating charac-
teristic (ROC) analysis of MBL levels predicting CVD in SLE patients was performed, but could not identify a 
candidate cut-off level (area under the curve (AUC) 0.529, Fig. 3).
Similarly, the distribution of MBL levels in subgroup analyses (Supplemental Table 1 and Fig. 2b) did not differ 
significantly. Of note, mesenteric insufficiency was recorded only once in the whole study population.
Furthermore, our analyses showed that MBL, neither below the deficiency cut-offs nor as a continuous param-
eter, does not associate with the included confounders including disease duration (data not shown). Likewise, 
ethnicity was not associated with the occurrence of CVD.
Association of CVD with risk factors and confounders. With regard to common CVD risk factors, more than half 
of the patients (52.3%) had hypercholesterolemia, 41.5% had arterial hypertension, 6,7% were diabetic, more than 
one-third (35.2%) were overweight with a BMI ≥ 25 kg/m2 and 42.4% had at least smoked once in their life. In 
addition, 43.7% of our patients had APL+.
As shown in Table 2, disease duration was longer in patients who had CVD than in those without (median 
20.0 vs 8.9 years, p < 0.001). In addition, patients with CVD were older (median age 57.5 vs. 41.9 years, p < 
0.001), more likely to be men (22.6% vs. 12.9%, p = 0.047), more frequently smokers (57.1% vs. 39.5%, p = 
0.015), more likely to have comorbidities associated with CVD (hypertension 71.7% vs. 35.2%, p < 0.001, hyper-
cholesteremia 92% vs. 42.7, p < 0.001, p = 0.1, APL+ 62.3% vs. 40.0%, p < 0.001, DM 11.3% vs. 5.8%) (Fig. 4) 
and accrued more damage overall (median SLICC index 2.8 vs. 1.8, p = 0.5). The same results in terms of signifi-
cance pertained to the CVD subcategories.
The ESR median in patients with CVD was 18.5 mm/h vs. 16.0 mm/h in patients without CVD (p = 0.3). ESR 
or the dose of PDN were not associated with the incidence of cardiovascular events in the present study (data not 
shown).
Figure 1. Correlation of MBL levels measured in 120 individuals at two different time points (2014 and 2018). 
MBL levels between different samples from the same patient correlated significantly as determined in the 
Spearman Rank Correlation (Correlation Coefficient 0.946, p < 0.001 (2-tailed)).
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Risk stratification of CVD with potential confounders. Adjusting the risk of CVD for MBL levels, potential and 
traditional CV risk factors, revealed a significant association of CVD with male sex (p = 0.05), age (p < 0.001), 
disease duration (p < 0.001), APL+ (p < 0.001), hypertension (p < 0.001), hypercholesterolemia (p < 0.001) 
and history of smoking (p = 0.02) in the univariate analysis, while the association with MBL levels p = 0.34), 
disease activity (SLEDAI p = 0.9, PGA p = 0.56), BMI (p = 0.58) and DM (p = 0.12) did not reach statistical 
significance. The final multiple logistic regression model including significant variables in the univariate analysis 
(with the exception of hypercholesterolemia due to missing values in two third of the patients) revealed an inde-
pendent significant association between CVD in SLE patients with age (p < 0.001), disease duration (p < 0.001), 
hypertension (p < 0.005) and APL+ (p < 0.003), while the association with male sex (p = 0.49) and smoking (p 
= 0.26) did not reach significance anymore (Fig. 4).
Non-CVD n = 
311 (83.4%)
CVD n = 62 
(16.6%) p-value
Age (in years), median (IQR) 41.9 (33.5–53.3) 57.5 (46.0–67.7) <0.001*
Disease Duration (in years), median (IQR) 8.9 (5.1–16.0) 20.0 (7.0–30.3) <0.001*
Disease Activity
            SLEDAI ≥ 6, n (%) 138/311 (44.4) 27/62 (43.5) 1.0
            PGA ≥ 1, n (%) 168/311 (54.0) 31/62 (50.0) 0.6
            SLICC, median (IQR) 1.8 (0–5.1) 2.8 (1.0–6.5) 0.5
Gender 0.047*
            Female, n (%) 271/311 (87.1) 48/62 (77.4)
            Male, n (%) 40/311 (12.9) 14/62 (22.6)
Ethnic background 0.9
MBL Level (in ng/ml), median (IQR) 1180 (339–2344) 955 (306–2389) 0.5
            <500 ng/ml, n (%) 104/311 (33.4) 25/62 (40.3) 0.3
            <1000 ng/ml, n (%) 144/311 (46.3) 31/62 (50.0) 0.6
Diabetes mellitus, n (%) 18/311 (5.8) 7/62 (11.3) 0.1
Hypertension, n (%) 89/253 (35.2) 38/53 (71.7) <0.001*
Hypercholesterolemia, n (%) 44/103 (42.7) 23/25 (92) <0.001*
Nicotine: Ever-smoker 113/286 (39.5) 32/56 (57.1) 0.02*
Pack-years, median (IQR), n = 326/373 (87.4%) 0 (0–5) 7.3 (0–20.0) <0.001*
BMI (in kg/m2), median (IQR) 23.5 (20.6–26.6) 23.4 (21.0–26.8) 0.9
Positive Antiphospholipid Serology, n (%) 124/310 (40.0) 38/61 (62.3) <0.001*
Table 2. Distribution of SLE patients with and without cardiovascular disease according to confounders.  
n = 373, unless otherwise stated, * = statistical significant, IQR = interquartile range, % = percentage,  
SLE = Systemic Lupus Erythematosus, MBL = Mannose-binding Lectin, SLEDAI = Systemic Lupus 
Erythematosus Disease Activity Index, PGA = Physician’s Global Assessment, SLICC = Systemic Lupus 
International Collaborating Clinics damage assessment.
Figure 2. Distribution of MBL levels in 373 SLE patients (a) with at least one cardiovascular disease (CVD) 
and (b) with cardiovascular disease according to the subcategory. The horizontal lines depict the median 
values. (CVD - cardiovascular disease, CVI - cerebrovascular ischemia, CHD - coronary heart disease, MCI - 
myocardial infarction, PAD - peripheral artery disease).
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Discussion
Compared to the general population20 patients with SLE have an increased risk for CV morbidity and preclin-
ical atherosclerosis51,52. Traditional CV risk factors cannot fully explain this observation19, suggesting that SLE 
disease-specific factors may play an additional role53. Previous studies described deficiency of complement MBL 
to be related to CVD in the general population36 and in SLE patients54,55.
With a focus on patients with SLE, previous studies on MBL gene polymorphisms suggest that low-producing 
MBL genotypes are associated with increased intima-media thickness56 and arterial thrombosis, more specifically 
with coronary events55. This is in accordance with another study in which MBL-deficient SLE patients were found 
to have a 3.3 fold increased risk of CVD54.
However, Calvo-Alen et al. found an association of MBL deficiency with cerebrovascular incidents (CVI) but 
not with ischemic heart disease57, and Jönsen et al. could show that classical risk factors (smoking, hypertension, 
low alcohol intake, elevated triglyceride concentration) were relatively more important for the development of 
CVD than MBL deficiency58.
Our study was designed to elucidate whether MBL deficiency, based on the resulting blood concentrations, is 
also associated with an increased incidence of CVD in SLE patients. To address this question, we measured MBL 
plasma levels and investigated their potential association with clinical CV manifestation and with the main CV 
risk factors.
Our results suggest that MBL deficiency is not a determinant of CVD in SLE patients, independent of other 
risk factors.
In part, our findings are in contrast to data reported by previous studies. These differences can be explained 
by a number of factors. First, our study focused on the determination of plasma MBL concentrations and not 
the genotypes54,55,57,58. With regard to the variability of MBL levels within one genotype27,29, MBL plasma levels 
seem to be more discriminative in terms of immunological functionality36. Second, we focused on all CVD out 
of the 12 organ systems that are recorded by the SLICC damage index, including CVI, CHD, MCI PAD and 
mesenteric insufficiency. Garred et al.59 were the first to describe a higher frequency of thrombotic disease in SLE 
patients with MBL low-producing genotypes and this analysis was limited to arterial thrombosis in a later study 
by ∅hlenschlaeger et al.55, while Calvo-Alen et al.57 restricted their analysis to CVI. Of interest, Jönsen et al.58 
and Calvo-Alen et al.57 used a similar outcome as in our study, allowing a better direct comparison between the 
studies. While the latter one showed an association with CVI, the first one, similarly to our study, rather described 
traditional CV risk factors to be primarily associated with CVD.
In direct comparison with the study by Jönsen et al.58 our study population had a considerably shorter 
follow-up time (in years) (median (range) 14 (0–49) vs. median (IQR) 9.5 (5.2–18.1)) but a somewhat higher age 
(in years) of the patients (median (range) 40 (10–83) vs. median (IQR) 44.8 (34.6–57.5)).
Another parameter that needs to be considered is the limited number of patients and, as a consequence, the 
limited number of patients with CVD investigated in previous studies. In comparison, our study evaluated a 
larger study population than the studies by ∅hlenschlaeger et al.55, Jönsen et al.58 and Font et al.54 but slightly less 
patients than the study by Calvo et al.57 Although in our study MBL deficiency was numerically more common in 
the group of SLE patients with CVD than in the Non-CVD group (40.3% vs. 33.4% below 500 ng/ml and 50.0% 
vs. 46.3% below 1000 ng/ml), this difference was not significant, which could be due to the relatively small num-
ber of events in total. In this context, it is of interest to note that patients in the study by ∅hlenschlaeger et al.55  
developed an arterial thrombosis in 26%, a frequency 10% higher than in our study population. Likewise, 
Figure 3. ROC analysis of MBL levels in the prediction of cardiovascular events in SLE patients. The dots 
represent empirical values of true/false fractions for MBL levels of 0–10,000 ng/ml in increments of CVD. The 
test characteristics.
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Calvo-Alen et al.57, Jönsen et al.58 and Font et al.54 showed a considerably higher rate of CV events, which might 
be related to the younger age of our SLE patients and the relatively short follow-up time in our study. As a con-
sequence, in spite of the relatively large number of SLE patient, our study might be limited in power due to its 
comparatively small number of CVD in total.
A further limitation that needs to be mentioned is that the damage assessment was carried out using the 
SLICC index and not with a specific focus on CVD at the time of data collection. Last, risk stratification analyses 
could not be adjusted to the thyroid function, but, according to our database records, the vast majority of our 
patients had no evidence of thyroid disease.
In balance with these limitations, the strength of our study is the large cohort size of SLE patients being 
prospectively included in the Swiss SLE Cohort Study (SSCS). The study population included both genders in 
Figure 4. Risk of CVD adjusted for common CV risk factors, APS and MBL levels by univariate and 
multivariate regression analysis. (a) The univariate logistic regression model was performed for MBL levels, sex, 
age, hypertension, smoking, hypercholesterolemia, BMI, disease activity scores as well as APS. (b) We included 
significant predictors into the multivariate analysis. Due to missing data, hypercholesterolemia had to be 
excluded to gain explanatory power.
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a typical distribution as observed in patients with SLE and was shown to have typical patient characteristics. In 
addition, we focused on the determination of plasma MBL concentrations which maybe best reflect functionality. 
MBL levels in our patients were found to be stable over time and not related to SLE disease activity.
In this setting, we could not find a significant association between MBL deficiency and the occurrence of CVD 
in SLE patients. However, large prospective studies with long follow-ups would be required to definitely exclude 
a role of MBL in SLE-associated CVD.
Data availability
The data generated or analyzed during the current study are available from the corresponding author on 
reasonable request.
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